Facebook Linkedin RSS Twitter Youtube
Home 2024

Intellia Therapeutics

Top 10 Publicly Owned Gene Editing Therapy Companies
A-Lists

Top 10 Publicly Owned Gene Editing Therapy Companies

Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration
GEN Edge

Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration

Bittersweet Symphony: Verve’s Pause on VERVE-101 Narrows LNP-Delivery Strategy
GEN Edge

Bittersweet Symphony: Verve’s Pause on VERVE-101 Narrows LNP-Delivery Strategy

StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles
Drug Discovery

StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles

Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett
Bioprocessing

Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
GEN Edge

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar

PASTE, Don’t Cut: Genome Editing Tool Looks Beyond CRISPR and Prime
Genome Editing

PASTE, Don’t Cut: Genome Editing Tool Looks Beyond CRISPR and Prime

CRISPR’s Second Decade: Jennifer Doudna Looks Forward and Back
Genome Editing

CRISPR’s Second Decade: Jennifer Doudna Looks Forward and Back

Running Up That Hill: Nessan Bermingham on Close to the Edge
Close to the Edge

Running Up That Hill: Nessan Bermingham on Close to the Edge

“GEN Edge Live”: Analyzing the Latest Milestones in Genome Editing
GEN Edge

“GEN Edge Live”: Analyzing the Latest Milestones in Genome Editing

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.